| Pipeline

CBL-514 is an investigational injection from Caliway Biopharmaceuticals that is being tested to reduce fat under the skin of the abdomen. It is not being tested as a weight-loss drug. As of November 19, 2026, two Phase 3 trials, SUPREME-01 and SUPREME-02, are registered on ClinicalTrials.gov and both list their status as recruiting. Neither has posted results, and no approval for CBL-514 was found in the sources checked.
CBL-514 is a development code. No generic name has been published that the Atlas could find, so it is listed here by code, along with the company study codes CBL-0301 (SUPREME-01) and CBL-0302 (SUPREME-02).
For readers who follow GLP-1 medicines such as tirzepatide (Zepbound, Mounjaro), these trials are a different kind of test. They enroll adults with a BMI under 30, they exclude people taking GLP-1 medicines or other weight-loss medicines, and the listed outcomes measure abdominal fat, not body weight.
Worth knowing: This page describes registry entries and company announcements. Phase 3 results have not been reported, so it cannot say whether CBL-514 works.
What the trials measure
Both trials give adults with moderate or severe abdominal fat either CBL-514 or a saltwater placebo (0.9% sodium chloride), injected under the skin of the abdomen. Each participant gets up to four treatments, once every four weeks, and each trial plans about 320 participants. The registry lists participants, investigators and outcome assessors as all blinded to who got which injection.
The main outcome, worded the same in both records, is the percentage of participants who improve by at least 2 grades on both the Patient Reported Abdominal Fat Rating Scale (PR-AFRS) and the Clinician Reported Abdominal Fat Rating Scale (CR-AFRS), comparing CBL-514 with placebo. It is measured from the start of the trial to 4 weeks after the final treatment. Each scale has 5 points, and in the Phase 2b paper moderate and severe abdominal fat correspond to grades 3 and 4. Requiring a 2-grade improvement on both scales means the clinician and the participant each have to see the change.
Two secondary outcomes are listed. One is the percent change in abdominal fat measured by MRI, a scan-based measure that does not depend on anyone's rating. The other is the share of participants who improve by at least 1 grade on both scales.
The registry lists no outcome for body weight or for visceral (deep abdominal) fat, and both trials exclude people with severe abdominal visceral fat. Safety and tolerability are in the trial titles, but neither record lists a safety outcome measure.
The company has described the endpoints differently from the registry. Its July 28, 2025 release for SUPREME-01 called the main endpoint a multicomponent responder endpoint that combines MRI fat volume with the patient-rated scale. Its May 22, 2026 release for SUPREME-02 named MRI fat volume and the patient-rated scale as the two primary endpoints. The registry records the two rating scales as primary and MRI as secondary. The Atlas did not find a public statistical analysis plan, so which version the final analysis follows is not known.
SUPREME-01 and SUPREME-02 side by side
Registry records checked on ClinicalTrials.gov on November 19, 2026. Dates are the registry's own and can change. Figures below summarize amounts and schedules reported in published research or circulating online. Listing a figure documents what is reported; it is not a recommendation and does not show a regimen is safe, effective, or appropriate for any person.
| Item | SUPREME-01 | SUPREME-02 |
|---|---|---|
| Registry number and company code | NCT07140939, CBL-0301 | NCT07526974, CBL-0302 |
| Status on November 19, 2026 | Recruiting. 6 of the 13 listed sites are recruiting; 7 are not yet recruiting. | Recruiting. 2 of the 15 listed sites are recruiting (Miami, Florida and Baton Rouge, Louisiana); 13 are not yet recruiting. |
| Study start | September 1, 2026 (actual) | November 9, 2026 (actual) |
| Primary completion and study completion (estimated) | July 2027 and September 2027 | August 2027 and October 2027 |
| Planned enrollment | 320 (estimated) | 320 (estimated) |
| Design | Phase 3, randomized, parallel groups, placebo-controlled. Participant, investigator and outcome assessor blinded. | Same as SUPREME-01. |
| Who can join (listed) | Adults 18 and older, BMI above 18.5 and below 30, weight at least 50 kg, moderate or severe abdominal fat on both scales. Excludes people on weight-loss medicines or programs or on GLP-1 medicines. Dissatisfaction with abdominal fat is rated on a scale from slightly dissatisfied to extremely dissatisfied. | Same listed criteria, except that dissatisfaction with abdominal fat is expressed on a Patient Self Rating Scale (PSRS). |
| Treatment schedule as registered (trial amounts) | Up to 4 treatments, 4 weeks apart. Up to 120 mL per treatment, with 50 injections. Placebo is 0.9% sodium chloride on the same schedule. | Up to 4 treatments, 4 weeks apart. Up to 120 mL per treatment (number of injections not stated). Placebo is 0.9% sodium chloride on the same schedule. |
| Primary outcome | At least a 2-grade improvement on both PR-AFRS and CR-AFRS, CBL-514 versus placebo, from baseline to 4 weeks after the final treatment. | Same wording and time frame. |
| Secondary outcomes | Percent change in abdominal fat on MRI. At least a 1-grade improvement on both scales. Same time frame. | Same two outcomes, same time frame. |
| Listed locations | 11 sites in the United States and 2 in Canada | 13 sites in the United States and 2 in Canada. No Australian site is listed, though the company's May 2026 release named Australia. |
| Results posted | None | None |
| Registry record first posted and last updated | First posted August 26, 2025. Last update posted October 19, 2026. | First posted April 14, 2026. Last update posted November 18, 2026. |
Sponsor for both: Caliway Biopharmaceuticals Co., Ltd. The registry gives injected volume, not drug concentration, so the amount of CBL-514 per injection cannot be worked out from these records. ClinicalTrials.gov notes that the U.S. government does not review or approve the safety and science of all studies it lists.
What FDA clearance to run a trial means
The company says FDA cleared the applications that let both trials go ahead. Its July 28, 2025 release says FDA granted clearance to proceed with SUPREME-01. Its May 22, 2026 release says the application for SUPREME-02 passed FDA's 30-day review period on May 18. The Atlas found these clearances in the company's releases and in press coverage of them, not in an FDA record.
The application involved is an Investigational New Drug (IND) application. FDA describes the IND as the way a sponsor obtains an exemption from the rule that a drug needs an approved marketing application before it is shipped across state lines. The sponsor waits 30 days after filing, which gives FDA a chance to review the application for safety, and then the trial can start.
So clearance to run a trial is permission to study the drug in people under the trial's rules. It is not marketing approval, and it is not a finding that CBL-514 works or that it is safe for use outside a study. Marketing approval comes only from a separate application filed after the trials report.
Earlier findings on injection-site firmness and contour
The Phase 3 trials follow a Phase 2b trial (NCT05736107) published by Lorenc and colleagues in Aesthetic Surgery Journal on May 20, 2026. Its abstract reports 108 adults randomized 1 to 1 to CBL-514 or placebo, up to four treatments 3 weeks apart, and a trial amount of 2 mg per square centimeter, up to 600 mg per treatment. In the abstract's full analysis set, 76.7% (23 of 30) of the CBL-514 group and 18.9% (7 of 37) of the placebo group improved by at least 1 grade on the clinician scale at 12 weeks. MRI showed an average decrease in abdominal fat volume of 152.9 mL (20.3%) from baseline, reported as significantly greater than placebo. The abstract describes injection-site reactions as mainly mild and transient. Several authors are affiliated with Caliway. The abstract's analysis set is smaller than the 108 randomized, and the abstract does not say why.
That trial differs from the Phase 3 design. It was single-blind, spaced treatments 3 weeks apart, and set its main goal at a 1-grade improvement on the clinician scale. The Phase 3 trials are listed as blinded for participants, investigators and assessors, space treatments 4 weeks apart, and ask for a 2-grade improvement on both scales.
Firmness at injection sites and questions about lasting lumps or uneven contour come up with injectable fat treatments. A plain-language look at the Phase 2b injection-site findings and the lump and contour questions goes through the reported firmness counts and why they cannot show how often lasting contour changes occur. The Atlas read only the Phase 2b abstract, which does not give firmness counts. Neither Phase 3 record lists an outcome for lasting contour changes. A Phase 3b long-term follow-up and open-label extension study (NCT07733947) is registered for people who finish either trial, with a planned December 2026 start, and it was not yet recruiting in the November 19 registry search.
What is still unknown about approval timing
- When results arrive. The registry estimates primary completion in July 2027 for SUPREME-01 and August 2027 for SUPREME-02. Sponsors can change those dates. The company's May 2026 release says clinical results are anticipated in 2027.
- How the schedule has moved. The July 2025 release expected recruitment to begin in the third quarter of 2025 and top-line results between the fourth quarter of 2026 and the first quarter of 2027, at 29 sites in the United States and Canada. The registry shows an actual start of September 1, 2026 for SUPREME-01 and lists 13 sites.
- Whether and when a filing happens. The company says the results are expected to support a future New Drug Application (NDA), the filing that asks FDA for marketing approval. No filing date has been given, and no NDA announcement was found as of November 19, 2026. After a filing, FDA review takes more time, and approval is not guaranteed.
- What an approval would cover. The proposed use the company has described is reduction of abdominal subcutaneous fat, which is not a weight-loss indication. Because the trials exclude people on GLP-1 medicines, their results would not speak to that group. A separate Phase 2 trial combining CBL-514 with tirzepatide (Zepbound) was announced by the company on August 25, 2026 as cleared by FDA to proceed; no registry entry for it turned up in a November 19 search of CBL-514 trials.
- How long any effect lasts. The main outcome is measured 4 weeks after the last treatment. Longer follow-up is planned in the Phase 3b study above but has not started.
- Which endpoints count. The registry and the company's releases describe the main endpoints differently, as covered above.
Where it stands
As of November 19, 2026, CBL-514 has two Phase 3 trials recruiting, no posted results, no announced marketing application and no approval found. The next facts that would change this page are the first Phase 3 results, which the registry does not expect before mid-2027, and any NDA announcement.
Sources
- A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat (SUPREME-01), NCT07140939 ClinicalTrials.gov, record read November 19, 2026; last update posted October 19, 2026. Trial registry
- A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat (SUPREME-02), NCT07526974 ClinicalTrials.gov, record read November 19, 2026; last update posted November 18, 2026. Trial registry
- ClinicalTrials.gov search for CBL-514 as an intervention, run November 19, 2026: 16 studies, including the Phase 3b follow-up study NCT07733947 and the Phase 2b trial NCT05736107. Trial registry search
- Caliway Announces FDA Clearance of IND Application for CBL-514 to Proceed with SUPREME-01 Caliway Biopharmaceuticals, July 28, 2025 (BioSpace copy). Company press release
- Caliway Announces U.S. FDA IND Clearance for CBL-0302, Its Second Global Pivotal Phase 3 Study of CBL-514 Caliway Biopharmaceuticals, May 22, 2026 (BioSpace copy). Company press release
- Caliway's CBL-514 Combination Therapy Cleared by U.S. FDA for Phase 2 Trial; Pivotal Phase 3 Trial SUPREME-01 Initiates Enrollment Caliway Biopharmaceuticals, August 25, 2026. Read in excerpts only. Company press release
- Investigational New Drug (IND) Application U.S. Food and Drug Administration. Regulator page
- Randomized Phase 2b Trial of CBL-514 Injection for Abdominal Subcutaneous Fat Reduction With Clinician- and Patient-reported Outcomes and MRI Assessment Lorenc ZP, Gold M, Schlessinger J, et al. Aesthetic Surgery Journal, online May 20, 2026; PubMed 42159040. Abstract read; full text not read. Several authors are affiliated with the sponsor. Peer-reviewed paper